Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus TAVIST ALLERGY SINUS HEADACHE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus TAVIST ALLERGY SINUS HEADACHE.
CLARINEX-D 12 HOUR vs TAVIST ALLERGY/SINUS/HEADACHE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
TAVIST ALLERGY/SINUS/HEADACHE contains clemastine fumarate (first-generation antihistamine) that competitively antagonizes histamine at H1 receptors, and acetaminophen that inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and fever; phenylpropanolamine is an alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
1 tablet (acetaminophen 500 mg, diphenhydramine 12.5 mg, phenylephrine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets per day
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
5-7 hours for clemastine; 12-15 hours for pseudoephedrine; acetaminophen half-life 2-3 hours. Context: Clemastine half-life supports twice-daily dosing; pseudoephedrine's longer half-life allows 6-8 hour dosing intervals
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal excretion of unchanged drug and metabolites accounts for 70-80%, with 15-25% fecal elimination; bilary excretion contributes to remaining
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination